Overview

P7C3 (pool 7, compound 3) is a small-molecule aminopropyl carbazole identified through an unbiased in vivo phenotypic screen for compounds that enhance hippocampal neurogenesis in adult mice, conducted at the University of Texas Southwestern Medical Center. Unlike target-based drug discovery, this approach selected for compounds with demonstrated in vivo neurogenic activity regardless of mechanism, and P7C3 emerged as the most potent hit from a library of approximately 1,000 compounds. The discovery represented a significant advance in neuroprotective pharmacology, as P7C3 and its optimized analog P7C3-A20 demonstrated exceptional efficacy across a remarkably broad range of neurodegenerative and neuropsychiatric disease models, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), traumatic brain injury, age-related cognitive decline, and depression.

The primary mechanism of P7C3's neuroprotective activity involves enhancement of nicotinamide phosphoribosyltransferase (NAMPT) — the rate-limiting enzyme in the NAD+ salvage pathway. By stabilizing and potentiating NAMPT activity, P7C3 maintains intracellular NAD+ levels under conditions of metabolic stress, preventing the bioenergetic crisis that triggers neuronal apoptosis. NAD+ is essential for mitochondrial oxidative phosphorylation, DNA repair (via PARP enzymes), sirtuin-mediated stress responses, and calcium homeostasis — all processes that become compromised during neurodegeneration. In hippocampal neurogenesis, P7C3 specifically protects newborn neurons during the critical period of integration (2–3 weeks post-mitosis) when approximately 70–80% of new neurons normally undergo programmed cell death. This pro-survival effect, combined with downstream enhancement of BDNF signaling and mitochondrial membrane stabilization, produces robust increases in functional neurogenesis. P7C3's activity thus complements that of BDNF-enhancing compounds like P21 and Semax, which stimulate neuronal birth, by ensuring the survival of newly generated neurons.

P7C3 and its analogs are administered orally and demonstrate good pharmacokinetic properties including blood-brain barrier penetration, oral bioavailability, and a favorable safety profile in preclinical testing. Research doses in rodent models typically range from 10–30 mg/kg. While P7C3 has not yet entered formal clinical trials, its mechanism through NMN/NAD+ pathway stabilization makes it conceptually synergistic with NAD+ precursors such as NMN or NR, as well as with direct neurotrophic agents like Dihexa. P7C3 remains a research tool compound with significant translational potential for neurodegenerative diseases characterized by impaired neurogenesis and NAD+ depletion.

Mechanism of Action

Mechanism of Action

P7C3 is an aminopropyl carbazole compound discovered through an in vivo screen for proneurogenic agents. Unlike many neurogenesis-enhancing compounds that stimulate progenitor proliferation, P7C3 acts primarily by protecting newborn neurons from programmed cell death.

NAD+ Biosynthesis Enhancement

The molecular target of P7C3 is nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in the mammalian NAD+ salvage pathway. P7C3 binds to and enhances NAMPT activity, increasing the conversion of nicotinamide to nicotinamide mononucleotide (NMN) and subsequently to NAD+. Elevated NAD+ levels support sirtuin-dependent mitochondrial maintenance and cellular energy metabolism.

Mitochondrial Protection

Newborn neurons are exceptionally vulnerable to metabolic stress during the first 1-2 weeks after birth. P7C3 maintains mitochondrial membrane integrity by ensuring adequate NAD+ supply for Complex I of the electron transport chain. This prevents ΔΨm collapse, blocks mitochondrial permeability transition pore (mPTP) opening, and inhibits the release of pro-apoptotic factors including cytochrome c and apoptosis-inducing factor (AIF).

Neuroprotective Selectivity

P7C3 shows particular efficacy in protecting immature neurons in the hippocampal dentate gyrus during their vulnerable integration period. Under normal conditions, approximately 80% of newborn hippocampal neurons die via apoptosis. P7C3 dramatically reduces this attrition, resulting in a larger pool of mature, functional granule cells.

Therapeutic Breadth

The NAD+-dependent mechanism gives P7C3 broad neuroprotective properties beyond neurogenesis, including protection against traumatic brain injury, amyotrophic lateral sclerosis, and Parkinson's disease in preclinical models.

Reconstitution Calculator

Research

Safety Profile

P7C3 is an investigational neuroprotective compound with limited human clinical data. Preclinical studies suggest a favorable safety profile, but potential side effects and drug interactions in humans are not well characterized. It should be avoided during pregnancy and by individuals with liver impairment, and use should be supervised by a qualified healthcare professional.

Pharmacokinetic Profile